Indeed, a recent phase III trial (METRIC study) involving patients with advanced or metastatic melanoma harboring B-RAFV600E/k mutant and without prior brain metastases (n = 332) reported the great efficacy of a reversible and highly selective allosteric inhibitor of MEK1/2 activity, trametinib (formerly GSK 1120212), when compared with “chemotherapy” (DITC or paclitaxel, but not vemurafenib) [52]. This evidence concerns the gene MAP2K1 and metastatic melanoma.